{"id":1866,"date":"2026-09-29T20:04:18","date_gmt":"2026-09-30T00:04:18","guid":{"rendered":"https:\/\/canasanta.ca\/?p=1866"},"modified":"2026-09-29T20:04:18","modified_gmt":"2026-09-30T00:04:18","slug":"una-nueva-arma-contra-la-diabetes","status":"publish","type":"post","link":"https:\/\/canasanta.ca\/en\/al-dia\/una-nueva-arma-contra-la-diabetes\/","title":{"rendered":"A NEW WEAPON AGAINST DIABETES"},"content":{"rendered":"

Una nueva pastilla experimental consigui\u00f3 reducir con fuerza los niveles de az\u00facar en pacientes con diabetes tipo 2. Se llama safiglipron, se toma una vez al d\u00eda, no necesita ayuno y ya complet\u00f3 ensayos cl\u00ednicos fase 3. China estudia actualmente su autorizaci\u00f3n.<\/em><\/strong><\/h3>\n

La diabetes tipo 2<\/strong><\/em> afecta a cientos de millones de personas en todo el mundo y obliga a muchos pacientes a convivir durante a\u00f1os con medicamentos, controles constantes y, en algunos casos, inyecciones. Ahora, una nueva pastilla podr\u00eda ampliar considerablemente las opciones disponibles.<\/p>\n

Se llama safiglipron<\/strong> y pertenece a la familia de medicamentos que act\u00faan sobre el receptor GLP-1, el mismo sistema utilizado por f\u00e1rmacos conocidos como Ozempic, Wegovy o Rybelsus. La diferencia es que safiglipron es una peque\u00f1a mol\u00e9cula dise\u00f1ada para administrarse f\u00e1cilmente por v\u00eda oral.<\/p>\n

Un ensayo fase 3 publicado este 29 de septiembre en Nature Medicine<\/em> evalu\u00f3 el medicamento en 284 personas con diabetes tipo 2 que todav\u00eda no utilizaban otros f\u00e1rmacos para controlar la glucosa.<\/p>\n

Despu\u00e9s de 32 semanas, los pacientes que recibieron safiglipron redujeron su HbA1c entre aproximadamente 1,4 y 1,6 puntos porcentuales<\/strong>, dependiendo de la dosis. En el grupo que recibi\u00f3 placebo, la reducci\u00f3n fue de apenas 0,18 puntos.<\/p>\n

El resultado m\u00e1s llamativo fue que alrededor de tres de cada cuatro pacientes tratados consiguieron llevar su HbA1c por debajo de 7%, uno de los objetivos habituales en el tratamiento de la diabetes. En las dosis m\u00e1s altas, una parte de los participantes incluso alcanz\u00f3 niveles considerados normales. Eso no significa que la diabetes haya sido curada.<\/p>\n

Para hablar de remisi\u00f3n, el paciente debe mantener niveles de glucosa fuera del rango diab\u00e9tico durante un per\u00edodo prolongado sin utilizar medicamentos. En este estudio, los participantes segu\u00edan tomando safiglipron. Por ahora, estamos hablando de un tratamiento muy prometedor, no de una cura.<\/p>\n

 <\/p>\n

Una pastilla sin ayuno<\/em><\/h2>\n

Aqu\u00ed aparece una de sus ventajas m\u00e1s interesantes. Rybelsus<\/strong> ya ofrece semaglutida en forma de pastilla, pero debe tomarse en ayunas y el paciente tiene que esperar antes de comer, beber o tomar otros medicamentos.<\/p>\n

Safiglipron fue administrado una vez al d\u00eda sin necesidad de ayuno ni restricciones con los alimentos<\/strong>. Para alguien que debe tomar un medicamento todos los d\u00edas durante a\u00f1os, esa facilidad puede convertirse en una diferencia importante.<\/p>\n

Tambi\u00e9n produjo p\u00e9rdida de peso. Con la dosis m\u00e1s alta, los pacientes perdieron en promedio cerca de un 4,8% de su peso corporal durante las 32 semanas del estudio.<\/p>\n

Los efectos secundarios m\u00e1s frecuentes fueron problemas gastrointestinales, algo habitual en los medicamentos GLP-1<\/strong>. La mayor\u00eda fueron leves o moderados.<\/p>\n

 <\/p>\n

Tambi\u00e9n fue comparada con otro medicamento<\/em><\/h2>\n

Otro ensayo fase 3 incluy\u00f3 a m\u00e1s de 800 pacientes que ya tomaban metformina<\/strong>. En este estudio, safiglipron<\/strong> fue comparada directamente con dapagliflozina<\/strong>, un medicamento ampliamente utilizado para tratar la diabetes tipo 2.<\/p>\n

La reducci\u00f3n de HbA1c<\/em> con safiglipron lleg\u00f3 hasta aproximadamente 1,68 puntos porcentuales<\/strong>, frente a 1,28 con dapagliflozina. Todas las dosis cumplieron los criterios establecidos por los investigadores y la dosis m\u00e1s alta consigui\u00f3 una reducci\u00f3n superior de glucosa.<\/p>\n

Eso no significa que un medicamento pueda reemplazar autom\u00e1ticamente al otro. Dapagliflozina tiene beneficios demostrados para determinados pacientes con problemas card\u00edacos o renales que safiglipron todav\u00eda tendr\u00e1 que demostrar en estudios a largo plazo.<\/p>\n

Tampoco podemos afirmar todav\u00eda que sea mejor que metformina o Rybelsus. Cada uno tiene ventajas diferentes y safiglipron todav\u00eda necesita acumular mucha m\u00e1s evidencia.<\/p>\n

 <\/p>\n

\u00bfCu\u00e1ndo estar\u00e1 disponible?<\/em><\/h2>\n

Esta es probablemente la parte m\u00e1s importante de la noticia. Safiglipron ya complet\u00f3 ensayos fase 3 para diabetes tipo 2 en China<\/strong>, y su fabricante present\u00f3 una solicitud para comercializarla. La autoridad regulatoria china acept\u00f3 oficialmente esa solicitud a comienzos de septiembre.<\/p>\n

Eso significa que el medicamento ya est\u00e1 siendo evaluado para una posible aprobaci\u00f3n. Todav\u00eda no existe una fecha oficial para su salida al mercado.<\/p>\n

En Estados Unidos, Canad\u00e1 y Europa tampoco hay una fecha anunciada. Los derechos internacionales pertenecen a Kailera Therapeutics, que contin\u00faa desarrollando el medicamento y realizando nuevos estudios. Por tanto, nadie debe esperar encontrar safiglipron ma\u00f1ana en una farmacia. Pero tampoco estamos ante una mol\u00e9cula experimental que acaba de aparecer en un laboratorio. Ha llegado a la \u00faltima etapa cl\u00ednica antes de una posible comercializaci\u00f3n.<\/p>\n

 <\/p>\n

Un cambio que ya comenz\u00f3<\/em><\/h2>\n

La verdadera importancia de safiglipron quiz\u00e1s no est\u00e9 solamente en este medicamento. Los laboratorios est\u00e1n compitiendo para convertir los tratamientos GLP-1 en pastillas cada vez m\u00e1s f\u00e1ciles de tomar, con menos restricciones y buenos resultados tanto para controlar la glucosa como para reducir peso.<\/p>\n

Durante a\u00f1os, algunos de los tratamientos m\u00e1s potentes contra la diabetes necesitaron inyecciones. Eso est\u00e1 cambiando.<\/p>\n

Safiglipron<\/em> todav\u00eda no cura la diabetes y quedan preguntas importantes sobre su seguridad y sus beneficios a largo plazo. Pero los resultados publicados hasta ahora colocan a esta peque\u00f1a pastilla entre los tratamientos que vale la pena observar muy de cerca.<\/p>","protected":false},"excerpt":{"rendered":"

Una nueva pastilla experimental consigui\u00f3 reducir con fuerza los niveles de az\u00facar en pacientes con diabetes tipo 2. Se llama safiglipron, se toma una vez al d\u00eda, no necesita ayuno y ya complet\u00f3 ensayos cl\u00ednicos fase 3. China estudia actualmente su autorizaci\u00f3n. La diabetes tipo 2 afecta a cientos de millones de personas en todo […]<\/p>\n","protected":false},"author":284226809,"featured_media":1869,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_wpcom_ai_launchpad_first_post":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[33205457,33205441,2127],"tags":[33206335,33205880,33206328,33205873,33206330,33206331,33205939,33206332,33206334,33206333,33206329,33205887],"class_list":["post-1866","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-al-dia","category-medicina","category-salud","tag-dapagliflozina","tag-diabetes","tag-diabetes-tipo-2","tag-glp-1","tag-glucosa","tag-hba1c","tag-investigacion-medica","tag-medicamentos-para-diabetes","tag-metformina","tag-rybelsus","tag-safiglipron","tag-salud"],"acf":[],"yoast_head":"\nUNA NUEVA ARMA CONTRA LA DIABETES - Ca\u00f1asanta<\/title>\n<meta name=\"description\" content=\"Safiglipron, una nueva pastilla GLP-1 para diabetes tipo 2, logra fuertes reducciones de glucosa en fase 3 y ya busca autorizaci\u00f3n en China.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/canasanta.ca\/en\/daily\/una-nueva-arma-contra-la-diabetes\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"UNA NUEVA ARMA CONTRA LA DIABETES\" \/>\n<meta property=\"og:description\" content=\"Safiglipron, una nueva pastilla GLP-1 para diabetes tipo 2, logra fuertes reducciones de glucosa en fase 3 y ya busca autorizaci\u00f3n en China.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/canasanta.ca\/en\/daily\/una-nueva-arma-contra-la-diabetes\/\" \/>\n<meta property=\"og:site_name\" content=\"Ca\u00f1asanta\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-30T00:04:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/09\/CS_diabetes_new001.jpg?resize=1200,630&quality=85&strip=all&ssl=1\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Canasanta Online\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Canasanta Online\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/canasanta.ca\\\/al-dia\\\/una-nueva-arma-contra-la-diabetes\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/al-dia\\\/una-nueva-arma-contra-la-diabetes\\\/\"},\"author\":{\"name\":\"Canasanta Online\",\"@id\":\"https:\\\/\\\/canasanta.ca\\\/#\\\/schema\\\/person\\\/21421a3c6f1733be6c5c590190fd8e93\"},\"headline\":\"UNA NUEVA ARMA CONTRA LA DIABETES\",\"datePublished\":\"2026-09-30T00:04:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/al-dia\\\/una-nueva-arma-contra-la-diabetes\\\/\"},\"wordCount\":849,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/al-dia\\\/una-nueva-arma-contra-la-diabetes\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/i0.wp.com\\\/canasanta.ca\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/CS_diabetes_new001.jpg?fit=1200%2C631&quality=82&strip=all&ssl=1\",\"keywords\":[\"dapagliflozina\",\"diabetes\",\"diabetes tipo 2\",\"GLP-1\",\"glucosa\",\"HbA1c\",\"investigaci\u00f3n m\u00e9dica\",\"medicamentos para diabetes\",\"metformina\",\"Rybelsus\",\"safiglipron\",\"salud\"],\"articleSection\":[\"AL D\u00cdA!\",\"Medicina\",\"Salud\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/canasanta.ca\\\/al-dia\\\/una-nueva-arma-contra-la-diabetes\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/canasanta.ca\\\/al-dia\\\/una-nueva-arma-contra-la-diabetes\\\/\",\"url\":\"https:\\\/\\\/canasanta.ca\\\/al-dia\\\/una-nueva-arma-contra-la-diabetes\\\/\",\"name\":\"UNA NUEVA ARMA CONTRA LA DIABETES - Ca\u00f1asanta\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/al-dia\\\/una-nueva-arma-contra-la-diabetes\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/al-dia\\\/una-nueva-arma-contra-la-diabetes\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/i0.wp.com\\\/canasanta.ca\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/CS_diabetes_new001.jpg?fit=1200%2C631&quality=82&strip=all&ssl=1\",\"datePublished\":\"2026-09-30T00:04:18+00:00\",\"description\":\"Safiglipron, una nueva pastilla GLP-1 para diabetes tipo 2, logra fuertes reducciones de glucosa en fase 3 y ya busca autorizaci\u00f3n en China.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/al-dia\\\/una-nueva-arma-contra-la-diabetes\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/canasanta.ca\\\/al-dia\\\/una-nueva-arma-contra-la-diabetes\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/canasanta.ca\\\/al-dia\\\/una-nueva-arma-contra-la-diabetes\\\/#primaryimage\",\"url\":\"https:\\\/\\\/i0.wp.com\\\/canasanta.ca\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/CS_diabetes_new001.jpg?fit=1200%2C631&quality=82&strip=all&ssl=1\",\"contentUrl\":\"https:\\\/\\\/i0.wp.com\\\/canasanta.ca\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/CS_diabetes_new001.jpg?fit=1200%2C631&quality=82&strip=all&ssl=1\",\"width\":1200,\"height\":631},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/canasanta.ca\\\/al-dia\\\/una-nueva-arma-contra-la-diabetes\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/canasanta.ca\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"UNA NUEVA ARMA CONTRA LA DIABETES\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/canasanta.ca\\\/#website\",\"url\":\"https:\\\/\\\/canasanta.ca\\\/\",\"name\":\"Ca\u00f1asanta\",\"description\":\"Magazine\",\"publisher\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/canasanta.ca\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/canasanta.ca\\\/#organization\",\"name\":\"Ca\u00f1asanta\",\"url\":\"https:\\\/\\\/canasanta.ca\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/canasanta.ca\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/i0.wp.com\\\/canasanta.ca\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/Logo.png?fit=2129%2C718&quality=82&strip=all&ssl=1\",\"contentUrl\":\"https:\\\/\\\/i0.wp.com\\\/canasanta.ca\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/Logo.png?fit=2129%2C718&quality=82&strip=all&ssl=1\",\"width\":2129,\"height\":718,\"caption\":\"Ca\u00f1asanta\"},\"image\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/canasanta.ca\\\/#\\\/schema\\\/person\\\/21421a3c6f1733be6c5c590190fd8e93\",\"name\":\"Canasanta Online\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/925594ac8e278f26e2e7403182642a1af3a9d1885cb6168deb61adb801ffd2b3?s=96&d=identicon&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/925594ac8e278f26e2e7403182642a1af3a9d1885cb6168deb61adb801ffd2b3?s=96&d=identicon&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/925594ac8e278f26e2e7403182642a1af3a9d1885cb6168deb61adb801ffd2b3?s=96&d=identicon&r=g\",\"caption\":\"Canasanta Online\"},\"sameAs\":[\"http:\\\/\\\/canasantaonline-pbuqn.wordpress.com\"],\"url\":\"https:\\\/\\\/canasanta.ca\\\/en\\\/author\\\/canasantaonline\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"UNA NUEVA ARMA CONTRA LA DIABETES - Ca\u00f1asanta","description":"Safiglipron, una nueva pastilla GLP-1 para diabetes tipo 2, logra fuertes reducciones de glucosa en fase 3 y ya busca autorizaci\u00f3n en China.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/canasanta.ca\/en\/daily\/una-nueva-arma-contra-la-diabetes\/","og_locale":"en_US","og_type":"article","og_title":"UNA NUEVA ARMA CONTRA LA DIABETES","og_description":"Safiglipron, una nueva pastilla GLP-1 para diabetes tipo 2, logra fuertes reducciones de glucosa en fase 3 y ya busca autorizaci\u00f3n en China.","og_url":"https:\/\/canasanta.ca\/en\/daily\/una-nueva-arma-contra-la-diabetes\/","og_site_name":"Ca\u00f1asanta","article_published_time":"2026-09-30T00:04:18+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/09\/CS_diabetes_new001.jpg?resize=1200,630&quality=85&strip=all&ssl=1","type":"image\/jpeg"}],"author":"Canasanta Online","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Canasanta Online","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/canasanta.ca\/al-dia\/una-nueva-arma-contra-la-diabetes\/#article","isPartOf":{"@id":"https:\/\/canasanta.ca\/al-dia\/una-nueva-arma-contra-la-diabetes\/"},"author":{"name":"Canasanta Online","@id":"https:\/\/canasanta.ca\/#\/schema\/person\/21421a3c6f1733be6c5c590190fd8e93"},"headline":"UNA NUEVA ARMA CONTRA LA DIABETES","datePublished":"2026-09-30T00:04:18+00:00","mainEntityOfPage":{"@id":"https:\/\/canasanta.ca\/al-dia\/una-nueva-arma-contra-la-diabetes\/"},"wordCount":849,"commentCount":0,"publisher":{"@id":"https:\/\/canasanta.ca\/#organization"},"image":{"@id":"https:\/\/canasanta.ca\/al-dia\/una-nueva-arma-contra-la-diabetes\/#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/09\/CS_diabetes_new001.jpg?fit=1200%2C631&quality=82&strip=all&ssl=1","keywords":["dapagliflozina","diabetes","diabetes tipo 2","GLP-1","glucosa","HbA1c","investigaci\u00f3n m\u00e9dica","medicamentos para diabetes","metformina","Rybelsus","safiglipron","salud"],"articleSection":["AL D\u00cdA!","Medicina","Salud"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/canasanta.ca\/al-dia\/una-nueva-arma-contra-la-diabetes\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/canasanta.ca\/al-dia\/una-nueva-arma-contra-la-diabetes\/","url":"https:\/\/canasanta.ca\/al-dia\/una-nueva-arma-contra-la-diabetes\/","name":"UNA NUEVA ARMA CONTRA LA DIABETES - Ca\u00f1asanta","isPartOf":{"@id":"https:\/\/canasanta.ca\/#website"},"primaryImageOfPage":{"@id":"https:\/\/canasanta.ca\/al-dia\/una-nueva-arma-contra-la-diabetes\/#primaryimage"},"image":{"@id":"https:\/\/canasanta.ca\/al-dia\/una-nueva-arma-contra-la-diabetes\/#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/09\/CS_diabetes_new001.jpg?fit=1200%2C631&quality=82&strip=all&ssl=1","datePublished":"2026-09-30T00:04:18+00:00","description":"Safiglipron, una nueva pastilla GLP-1 para diabetes tipo 2, logra fuertes reducciones de glucosa en fase 3 y ya busca autorizaci\u00f3n en China.","breadcrumb":{"@id":"https:\/\/canasanta.ca\/al-dia\/una-nueva-arma-contra-la-diabetes\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/canasanta.ca\/al-dia\/una-nueva-arma-contra-la-diabetes\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/canasanta.ca\/al-dia\/una-nueva-arma-contra-la-diabetes\/#primaryimage","url":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/09\/CS_diabetes_new001.jpg?fit=1200%2C631&quality=82&strip=all&ssl=1","contentUrl":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/09\/CS_diabetes_new001.jpg?fit=1200%2C631&quality=82&strip=all&ssl=1","width":1200,"height":631},{"@type":"BreadcrumbList","@id":"https:\/\/canasanta.ca\/al-dia\/una-nueva-arma-contra-la-diabetes\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/canasanta.ca\/"},{"@type":"ListItem","position":2,"name":"UNA NUEVA ARMA CONTRA LA DIABETES"}]},{"@type":"WebSite","@id":"https:\/\/canasanta.ca\/#website","url":"https:\/\/canasanta.ca\/","name":"Ca\u00f1asanta","description":"Magazine","publisher":{"@id":"https:\/\/canasanta.ca\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/canasanta.ca\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/canasanta.ca\/#organization","name":"Ca\u00f1asanta","url":"https:\/\/canasanta.ca\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/canasanta.ca\/#\/schema\/logo\/image\/","url":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/09\/Logo.png?fit=2129%2C718&quality=82&strip=all&ssl=1","contentUrl":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/09\/Logo.png?fit=2129%2C718&quality=82&strip=all&ssl=1","width":2129,"height":718,"caption":"Ca\u00f1asanta"},"image":{"@id":"https:\/\/canasanta.ca\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/canasanta.ca\/#\/schema\/person\/21421a3c6f1733be6c5c590190fd8e93","name":"Canasanta Online","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/925594ac8e278f26e2e7403182642a1af3a9d1885cb6168deb61adb801ffd2b3?s=96&d=identicon&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/925594ac8e278f26e2e7403182642a1af3a9d1885cb6168deb61adb801ffd2b3?s=96&d=identicon&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/925594ac8e278f26e2e7403182642a1af3a9d1885cb6168deb61adb801ffd2b3?s=96&d=identicon&r=g","caption":"Canasanta Online"},"sameAs":["http:\/\/canasantaonline-pbuqn.wordpress.com"],"url":"https:\/\/canasanta.ca\/en\/author\/canasantaonline\/"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/phoxY0-u6","jetpack-related-posts":[{"id":1891,"url":"https:\/\/canasanta.ca\/en\/al-dia\/la-inyeccion-que-hace-perder-21-del-peso\/","url_meta":{"origin":1866,"position":0},"title":"THE INJECTION THAT CAUSES YOU TO LOSE 21% OF WEIGHT","author":"Canasanta Online","date":"September 29, 2026","format":false,"excerpt":"Un nuevo f\u00e1rmaco experimental de Eli Lilly logra una p\u00e9rdida media cercana a 50 libras en pacientes con obesidad y diabetes tipo 2. Los resultados de fase 3 colocan a retatrutide entre los tratamientos para adelgazar m\u00e1s potentes estudiados hasta ahora. Eli Lilly acaba de presentar nuevos resultados de retatrutide,\u2026","rel":"","context":"In "AL D\u00cdA!"","block_context":{"text":"AL D\u00cdA!","link":"https:\/\/canasanta.ca\/en\/category\/al-dia\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/09\/CS_inyeccion_diabetes001.jpg?fit=1200%2C628&quality=82&strip=all&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/09\/CS_inyeccion_diabetes001.jpg?fit=1200%2C628&quality=82&strip=all&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/09\/CS_inyeccion_diabetes001.jpg?fit=1200%2C628&quality=82&strip=all&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/09\/CS_inyeccion_diabetes001.jpg?fit=1200%2C628&quality=82&strip=all&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/09\/CS_inyeccion_diabetes001.jpg?fit=1200%2C628&quality=82&strip=all&ssl=1&resize=1050%2C600 3x"},"classes":[]},{"id":1861,"url":"https:\/\/canasanta.ca\/en\/al-dia\/la-ia-ya-aprendio-a-mentir\/","url_meta":{"origin":1866,"position":1},"title":"AI HAS ALREADY LEARNED TO LIE","author":"Canasanta Online","date":"September 29, 2026","format":false,"excerpt":"Agentes de inteligencia artificial de Alibaba, DeepSeek y Moonshot mintieron sobre sus capacidades, fabricaron resultados para ocultar fracasos y, en otros experimentos, llegaron a cruzar barreras dise\u00f1adas para contenerlos. No ocurri\u00f3 en una pel\u00edcula ni en un escenario futurista: ocurri\u00f3 en laboratorios durante pruebas realizadas con sistemas que ya existen.\u2026","rel":"","context":"In "AL D\u00cdA!"","block_context":{"text":"AL D\u00cdA!","link":"https:\/\/canasanta.ca\/en\/category\/al-dia\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/09\/CS_IA_miente_001.jpg?fit=1200%2C631&quality=82&strip=all&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/09\/CS_IA_miente_001.jpg?fit=1200%2C631&quality=82&strip=all&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/09\/CS_IA_miente_001.jpg?fit=1200%2C631&quality=82&strip=all&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/09\/CS_IA_miente_001.jpg?fit=1200%2C631&quality=82&strip=all&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/09\/CS_IA_miente_001.jpg?fit=1200%2C631&quality=82&strip=all&ssl=1&resize=1050%2C600 3x"},"classes":[]},{"id":1885,"url":"https:\/\/canasanta.ca\/en\/historia\/perforan-el-arca-de-noe\/","url_meta":{"origin":1866,"position":2},"title":"THEY DRILL INTO \u201cNOAH\u2019S ARK\u201d","author":"Canasanta Online","date":"September 29, 2026","format":false,"excerpt":"Investigadores comenzaron a perforar la misteriosa formaci\u00f3n de Durup\u0131nar, cerca del monte Ararat, despu\u00e9s de detectar con radar cavidades subterr\u00e1neas que podr\u00edan corresponder a corredores y espacios internos. Ahora las muestras extra\u00eddas del terreno podr\u00edan ayudar a determinar si estamos ante una simple formaci\u00f3n geol\u00f3gica o algo muy diferente. A\u2026","rel":"","context":"In "ARQUEOLOGIA"","block_context":{"text":"ARQUEOLOGIA","link":"https:\/\/canasanta.ca\/en\/category\/historia\/arqueologia\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/09\/CS_arca_noe_001.jpg?fit=1200%2C631&quality=82&strip=all&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/09\/CS_arca_noe_001.jpg?fit=1200%2C631&quality=82&strip=all&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/09\/CS_arca_noe_001.jpg?fit=1200%2C631&quality=82&strip=all&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/09\/CS_arca_noe_001.jpg?fit=1200%2C631&quality=82&strip=all&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/09\/CS_arca_noe_001.jpg?fit=1200%2C631&quality=82&strip=all&ssl=1&resize=1050%2C600 3x"},"classes":[]},{"id":1871,"url":"https:\/\/canasanta.ca\/en\/ufologia\/que-aparecio-detras-de-starship\/","url_meta":{"origin":1866,"position":3},"title":"WHAT APPEARED BEHIND STARSHIP?","author":"Canasanta Online","date":"September 29, 2026","format":false,"excerpt":"Una extra\u00f1a figura azulada apareci\u00f3 durante la transmisi\u00f3n oficial del vuelo 14 de Starship y, como era de esperar, desat\u00f3 todo tipo de especulaciones. La explicaci\u00f3n m\u00e1s razonable apunta a una nube de gases o residuos del propio vuelo, pero las im\u00e1genes por s\u00ed solas no permiten identificar con absoluta\u2026","rel":"","context":"In "AL D\u00cdA!"","block_context":{"text":"AL D\u00cdA!","link":"https:\/\/canasanta.ca\/en\/category\/al-dia\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/09\/CS_starship14_ovni_uap.jpg?fit=1200%2C631&quality=82&strip=all&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/09\/CS_starship14_ovni_uap.jpg?fit=1200%2C631&quality=82&strip=all&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/09\/CS_starship14_ovni_uap.jpg?fit=1200%2C631&quality=82&strip=all&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/09\/CS_starship14_ovni_uap.jpg?fit=1200%2C631&quality=82&strip=all&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/09\/CS_starship14_ovni_uap.jpg?fit=1200%2C631&quality=82&strip=all&ssl=1&resize=1050%2C600 3x"},"classes":[]}],"jetpack_featured_media_url":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/09\/CS_diabetes_new001.jpg?fit=1200%2C631&quality=82&strip=all&ssl=1","_links":{"self":[{"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/posts\/1866","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/users\/284226809"}],"replies":[{"embeddable":true,"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/comments?post=1866"}],"version-history":[{"count":3,"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/posts\/1866\/revisions"}],"predecessor-version":[{"id":1870,"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/posts\/1866\/revisions\/1870"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/media\/1869"}],"wp:attachment":[{"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/media?parent=1866"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/categories?post=1866"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/tags?post=1866"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}